Attenuated Modified Vaccinia Virus Ankara Can Be Used as an Immunizing Agent under Conditions of Preexisting Immunity to the Vector
- 15 August 2000
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 74 (16) , 7651-7655
- https://doi.org/10.1128/jvi.74.16.7651-7655.2000
Abstract
A problem associated with the use of vaccinia virus recombinants as vaccines is the existence of a large human population with preexisting immunity to the vector. Here we showed that after a booster with attenuated recombinant modified vaccinia virus Ankara (rMVA), higher humoral and cellular immune responses to foreign antigens (human immunodeficiency virus type 1 Env and β-galactosidase) were found in mice preimmunized with rMVA than in mice primed with the virulent Western Reserve strain and boosted with rMVA. This enhancement correlated with higher levels of expression of foreign antigens after the booster.Keywords
This publication has 25 references indexed in Scilit:
- Vaccination with two different vaccinia recombinant viruses: long-term inhibition of secondary vaccinationVaccine, 1993
- Class I major histocompatibility complex-restricted cytotoxic T cell responses to vaccinia virus in humansJournal of General Virology, 1993
- Overcoming inhibition of antibody responses to a malaria recombinant vaccinia virus caused by prior exposure to wild type virusVaccine, 1991
- Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoproteinThe Lancet, 1991
- Humoral immune response elicited by highly attenuated variants of vaccinia virus and by an attenuated recombinant expressing HIV-1 envelope proteinVirology, 1989
- Successful vaccination with a polyvalent live vector despite existing immunity to an expressed antigenNature, 1988
- Expression of the firefly luciferase gene in vaccinia virus: a highly sensitive gene marker to follow virus dissemination in tissues of infected animals.Proceedings of the National Academy of Sciences, 1988
- Recombinant Vaccinia Virus: Immunization Against Multiple PathogensScience, 1985
- Vaccinia Virus Recombinant Expressing Herpes Simplex Virus Type 1 Glycoprotein D Prevents Latent Herpes in MiceScience, 1985
- Construction of live vaccines using genetically engineered poxviruses: biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D.Proceedings of the National Academy of Sciences, 1984